A Phase 1 Study Investigating the Combination of AFM13 and the Monoclonal Anti-PD-1 Antibody Pembrolizumab in Patients with Relapsed/Refractory Hodgkin Lymphoma after Brentuximab Vedotin Failure: Updated Safety and Efficacy Data
AFM13 is a first-in-class tetravalent, bispecific NK cell engager that binds to CD30 on tumor cells and CD16A on NK cells. By engaging CD16-positive NK cells, AFM13 leads to NK cell-mediated killing of tumor cells.1 Pembrolizumab (Keytruda®) is approved in patients with R/R classical Hodgkin lymphoma as monotherapy. AFM13 showed single agent clinical activity with solid safety profile in a Phase 1 study2. Pre-clinical in vivo data of the combination of AFM13 with PD1-blockade showed synergism and the potential for induction of cross-talk between innate and adaptive immunity.3 Based on these findings, we conducted a Phase 1b study evaluating the safety and tolerability of AFM13 in combination with pembrolizumab in patients with R/R Hodgkin lymphoma
-
Most popular related searches
Related products
Customer comments
No comments were found for A Phase 1 Study Investigating the Combination of AFM13 and the Monoclonal Anti-PD-1 Antibody Pembrolizumab in Patients with Relapsed/Refractory Hodgkin Lymphoma after Brentuximab Vedotin Failure: Updated Safety and Efficacy Data. Be the first to comment!